Abstract
Pharmacological treatments of first episode schizophrenia are of particular relevance because most clinical and psychosocial deterioration with cognitive decline and changes in brain volume occurs in the first five years of disease onset. Although the efficacy of antipsychotic maintenance treatment has been demonstrated to reduce risk of relapse, nonadherence is common even in first episode schizophrenia patients. Antipsychotic long-acting injections (LAIs) could be an option in early treatment although international guidelines recommend their use in patients who have already experienced significant non-adherence and who have repeated relapse. At the present time there is some concern about the acceptability of LAIs in first episode schizophrenia: some studies suggest that LAI treatment is feasible in these patients because of distinct advantages in terms of better treatment adherence. In the present review, we analyze the few currently studies published on the use of risperidone long-acting injection (RLAI) to improve adherence in first episode schizophrenia. Further research is needed to support the routine use of LAIs and of the other second generation antipsychotic LAIs (olanzapine long-acting and paliperidone palmitato) in this population of patients to improve adherence.
Keywords: Adherence, antipsychotics, atypical antipsychotics, compliance, depot formulation, efficacy, first episode schizophrenia, long-acting injection, medication discontinuation, patients attitude, psychiatric attitude, relapse, remission, schizophrenia, tolerability
Current Psychopharmacology
Title:Risperidone Long-Acting Injection in the Treatment of First Episode Schizophrenia
Volume: 2
Author(s): P. Rocca, L. Sandei, I. M. Bava and T. Frieri
Affiliation:
Keywords: Adherence, antipsychotics, atypical antipsychotics, compliance, depot formulation, efficacy, first episode schizophrenia, long-acting injection, medication discontinuation, patients attitude, psychiatric attitude, relapse, remission, schizophrenia, tolerability
Abstract: Pharmacological treatments of first episode schizophrenia are of particular relevance because most clinical and psychosocial deterioration with cognitive decline and changes in brain volume occurs in the first five years of disease onset. Although the efficacy of antipsychotic maintenance treatment has been demonstrated to reduce risk of relapse, nonadherence is common even in first episode schizophrenia patients. Antipsychotic long-acting injections (LAIs) could be an option in early treatment although international guidelines recommend their use in patients who have already experienced significant non-adherence and who have repeated relapse. At the present time there is some concern about the acceptability of LAIs in first episode schizophrenia: some studies suggest that LAI treatment is feasible in these patients because of distinct advantages in terms of better treatment adherence. In the present review, we analyze the few currently studies published on the use of risperidone long-acting injection (RLAI) to improve adherence in first episode schizophrenia. Further research is needed to support the routine use of LAIs and of the other second generation antipsychotic LAIs (olanzapine long-acting and paliperidone palmitato) in this population of patients to improve adherence.
Export Options
About this article
Cite this article as:
Rocca P., Sandei L., M. Bava I. and Frieri T., Risperidone Long-Acting Injection in the Treatment of First Episode Schizophrenia, Current Psychopharmacology 2013; 2 (1) . https://dx.doi.org/10.2174/2211556011302010029
DOI https://dx.doi.org/10.2174/2211556011302010029 |
Print ISSN 2211-5560 |
Publisher Name Bentham Science Publisher |
Online ISSN 2211-5579 |
Call for Papers in Thematic Issues
Breakthroughs in drug design, development and delivery system for the management of neuro-psychiatric disorders
Neuropsychiatric diseases are one of the main causes of disability, affecting millions of people. Various drugs are used for its treatment, although no effective therapy has been found yet. The blood brain barrier (BBB) significantly complicates drugs delivery to the target cells in the brain tissues. This proposal describes the ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Cellular Mechanisms of Bypass Vein Graft Arterialization and Approaches to Attenuate Graft Remodeling
Vascular Disease Prevention (Discontinued) Oxycodone/Naloxone in the Management of Patients with Pain and Opioid–Induced Bowel Dysfunction
Current Drug Targets Molecular Effects Elicited In Vitro by Red Wine on Human Healthy Peripheral Blood Mononuclear Cells: Potential Therapeutical Application of Polyphenols to Diet-Related Chronic Diseases
Current Pharmaceutical Design Cannabinoid System as a Potential Target for Drug Development in the Treatment of Cardiovascular Disease
Current Vascular Pharmacology Mosquito and Tick-borne Illnesses in the United States. Guidelines for the Recognition and Empiric Treatment of Zoonotic Diseases in the Wilderness.
Infectious Disorders - Drug Targets Hypothalamic Glucose Sensing and Glycaemic Disease
Current Diabetes Reviews Advancement in Nanoparticle-based Biosensors for Point-of-care <i>In vitro</i> Diagnostics
Current Topics in Medicinal Chemistry Search and Rescue: Identification of Cannabinoid Actions Relevant for Neuronal Survival and Protection
Current Neuropharmacology Abnormal Saccadic Intrusions with Alzheimer's Disease in Darkness
Current Alzheimer Research Lipid Membrane; A Novel Target for Viral and Bacterial Pathogens
Current Drug Targets Hydrogel-clay Nanocomposites as Carriers for Controlled Release
Current Medicinal Chemistry Parkinson's Disease: A Role for the Immune System
Current Molecular Pharmacology Sweet on Hedgehogs: Regulatory Roles of Heparan Sulfate Proteoglycans in Hedgehog-Dependent Cell Proliferation and Differentiation
Current Protein & Peptide Science Current Aspects of Carbohydrate Structural Bioinformatics
Current Chemical Biology Observation of Pain in Dementia
Current Alzheimer Research Pharmacological Interventions and Rehabilitation Approach for Enhancing Brain Self-repair and Stroke Recovery
Current Neuropharmacology Genome-Wide Expression Analysis in Epilepsy: A Synthetic Review
Current Topics in Medicinal Chemistry Dopaminergic Modulation of Cognitive Control: Distinct Roles for the Prefrontal Cortex and the Basal Ganglia
Current Pharmaceutical Design Attention Deficit Hyperactive Disorder and Occurrence of Tic Disorders in Children and Adolescents—What is the Verdict
Current Pediatric Reviews Anticonvulsant Effect of the Essential Oil and Methanolic Extracts of <i>Zataria multiflora</i> Boiss
Central Nervous System Agents in Medicinal Chemistry